Patents by Inventor Irwin Chen
Irwin Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11692031Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 2, 2019Date of Patent: July 4, 2023Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Christoph Dahlhoff, Claudia Blümel, Johannes Brozy, Tobias Raum, Elisabeth Nahrwold, Tara Arvedson, Irwin Chen, Sandra Ross, Julie Bailis
-
Patent number: 11643440Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.Type: GrantFiled: June 1, 2018Date of Patent: May 9, 2023Assignee: AMGEN INC.Inventors: Irwin Chen, Su Chong, Essa Hu Harrington, Fang-Tsao Hong, Jason C. Long, Leslie P. Miranda
-
Publication number: 20220363770Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.Type: ApplicationFiled: June 26, 2020Publication date: November 17, 2022Applicant: AMGEN INC.Inventors: Irwin CHEN, Su CHONG, Fernando GARCES, Mark Leo MICHAELS, Christopher MOHR, Kenneth William WALKER, Zhulun WANG, Neeraj Jagdish AGRAWAL, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Derek E. PIPER, Cen XU
-
Publication number: 20220204611Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.Type: ApplicationFiled: September 28, 2021Publication date: June 30, 2022Inventors: Ian N. FOLTZ, Shilpa SAMBASHIVAN, Irwin CHEN, Susie Miki HARRIS, Dora TOLEDO WARSHAVIAK, Ian DRIVER, Daniel LU
-
Publication number: 20220195022Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.Type: ApplicationFiled: December 21, 2021Publication date: June 23, 2022Applicant: AMGEN INC.Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
-
Publication number: 20210395313Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.Type: ApplicationFiled: June 1, 2018Publication date: December 23, 2021Inventors: Irwin CHEN, Su CHONG, Essa Hu HARRINGTON, Fang-Tsao HONG, Jason C. LONG, Leslie P. MIRANDA
-
Patent number: 11186636Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.Type: GrantFiled: April 20, 2018Date of Patent: November 30, 2021Assignee: AMGEN INC.Inventors: Ian Foltz, Shilpa Sambashivan, Irwin Chen, Susie Miki Harris, Dora Toledo Warshaviak, Ian Driver, Daniel Lu
-
Publication number: 20210130465Abstract: The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and the Macaca CD3E chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.Type: ApplicationFiled: December 31, 2018Publication date: May 6, 2021Inventors: Tobias Raum, Tara Arvedson, Julie Bailis, Christoph Dahlhoff, Sandra Ross, Irwin Chen, Claudia Blümel, Elisabeth Nahrwold, Jochen Pendzialek, Joachim Wahl
-
Publication number: 20210087286Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.Type: ApplicationFiled: June 20, 2018Publication date: March 25, 2021Applicant: AMGEN INC.Inventors: Darren L. BATES, Donghui SHI, David J. LLOYD, Pavel BONDARENKO, Mark L. MICHAELS, Todd HAGER, Xiaoshan MIN, Aiko UMEDA, Irwin CHEN, Zhulun WANG
-
Publication number: 20210054069Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.Type: ApplicationFiled: April 20, 2018Publication date: February 25, 2021Applicant: AMGEN INC.Inventors: Ian Foltz, Shilpa Sambashivan, Irwin Chen, Susie Miki Harris, Dora Toledo Warshaviak, Ian Driver, Daniel Lu
-
Publication number: 20210017261Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.Type: ApplicationFiled: July 1, 2020Publication date: January 21, 2021Applicant: AMGEN INC.Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
-
Publication number: 20200055932Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: August 2, 2019Publication date: February 20, 2020Inventors: Christoph Dahlhoff, Claudia Blümel, Johannes Brozy, Tobias Raum, Elisabeth Nahrwold, Tara Arvedson, Irwin Chen, Sandra Ross, Julie Bailis
-
Publication number: 20190218279Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.Type: ApplicationFiled: January 11, 2019Publication date: July 18, 2019Applicant: AMGEN INC.Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
-
Publication number: 20180061257Abstract: Information via a tutorial or navigable environment where the navigable environment presents information to users via a navigable, layered user interface having various different information presentation schema or formats. rendering and presentation of an interactive, actionable, and/or navigable display of information is presented. A tutorial system renders and causes a user device to present a user-navigable series of categories associated with a specific topic based on underlying source documents via a user interface, and present sub-categories of information related to the specific topic as a user navigates various presented display elements.Type: ApplicationFiled: August 31, 2017Publication date: March 1, 2018Inventors: James Mintz, Irwin Chen, John Mintz, James Proctor, Ian Casewell
-
Patent number: 9708375Abstract: The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.Type: GrantFiled: March 14, 2014Date of Patent: July 18, 2017Assignee: Amgen Inc.Inventors: Ryan B. Case, Benjamin M. Alba, Alice Bakker, Irwin Chen, Amy N. Duguay, Monica Florio, Peng Li, Mark Leo Michaels, Mei-Mei Tsai
-
Publication number: 20160244747Abstract: Strategies, systems, methods, reagents, and kits for the directed evolution of bond-forming enzymes are provided herein. Evolution products, for example, evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are also provided herein, as are methods for using such evolved bond-forming enzymes. Kits comprising materials, reagents, and cells for carrying out the directed evolution methods described herein are also provided.Type: ApplicationFiled: February 22, 2016Publication date: August 25, 2016Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, Irwin Chen, Brent M. Dorr
-
Patent number: 9267127Abstract: Strategies, systems, methods, reagents, and kits for the directed evolution of bond-forming enzymes are provided herein. Evolution products, for example, evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are also provided herein, as are methods for using such evolved bond-forming enzymes. Kits comprising materials, reagents, and cells for carrying out the directed evolution methods described herein are also provided.Type: GrantFiled: June 20, 2013Date of Patent: February 23, 2016Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, Irwin Chen, Brent M. Dorr
-
Publication number: 20160024158Abstract: The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Inventors: Ryan B. CASE, Benjamin M. ALBA, Alice BAKKER, Irwin CHEN, Amy N. DUGUAY, Monica FLORIO, Peng LI, Mark Leo MICHAELS, Mei-mei TSAI
-
Publication number: 20140057317Abstract: Strategies, systems, methods, reagents, and kits for the directed evolution of bond-forming enzymes are provided herein. Evolution products, for example, evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are also provided herein, as are methods for using such evolved bond-forming enzymes. Kits comprising materials, reagents, and cells for carrying out the directed evolution methods described herein are also provided.Type: ApplicationFiled: June 20, 2013Publication date: February 27, 2014Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, Irwin Chen, Brent M. Dorr
-
Patent number: D839913Type: GrantFiled: July 5, 2017Date of Patent: February 5, 2019Inventors: Irwin Chen, James Proctor, Jim Mintz